Marie Hodges, PhD

University of Birmingham, United Kingdom

Poster(s):

• 1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

• 1711 - A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.

• 1713 - An assessment of NK and T cell functional immunity in response to vaccination whilst taking acalabrutinib or ibrutinib monotherapy.